Regulation of p53 expression and apoptosis by vault RNA2-1-5p in cervical cancer cells

Oncotarget

Volumn 6, Issue 29, 2015, Pages 28371-28388

  Kong, Lu ^a   Hao, Qi ^a   Wang, Ying ^a   Zhou, Ping ^a   Zou, Binbin ^a   Zhang, Yu xiang ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Cervical cancer; Non coding microRNAs; p53; VTRNA2 1 5p

Indexed keywords

CISPLATIN; PROTEIN P53; UNCLASSIFIED DRUG; UNTRANSLATED RNA; VAULT RNA2 1 5P; 3' UNTRANSLATED REGION; ANTINEOPLASTIC AGENT; MICRORNA; MIRN886 MICRORNA, HUMAN;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; APOPTOSIS; ARTICLE; BINDING AFFINITY; CANCER CELL; CARCINOGENICITY; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; GENE OVEREXPRESSION; GENE TARGETING; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; TUMOR INVASION; UTERINE CERVIX CANCER; ANIMAL; BAGG ALBINO MOUSE; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HELA CELL LINE; IN SITU HYBRIDIZATION; METABOLISM; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; NUDE MOUSE; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE; UTERINE CERVIX TUMOR; WESTERN BLOTTING; XENOGRAFT;

3' UNTRANSLATED REGIONS; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BASE SEQUENCE; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HELA CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MICE, INBRED BALB C; MICE, NUDE; MICRORNAS; MOLECULAR SEQUENCE DATA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSPLANTATION, HETEROLOGOUS; TUMOR SUPPRESSOR PROTEIN P53; UTERINE CERVICAL NEOPLASMS;

EID: 84944474497     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.4948     Document Type: Article

References (49)

1. Khan MJ, Castle PE, Lorincz AT, Wacholder S, Sherman M, Scott DR, Rush BB, Glass AG and Schiffman M. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst. 2005; 97:1072-1079.
2. Schmitz M, Driesch C, Jansen L, Runnebaum IB and Durst M. Non-random integration of the HPV genome in cervical cancer. PloS one. 2012; 7:e39632.
3. Au Yeung CL, Tsang TY, Yau PL and Kwok TT. Human papillomavirus type 16 E6 induces cervical cancer cell migration through the p53/microRNA-23b/urokinase-type plasminogen activator pathway. Oncogene. 2011; 30:2401-2410.
4. Martinez I, Gardiner AS, Board KF, Monzon FA, Edwards RP and Khan SA. Human papillomavirus type 16 reduces the expression of microRNA-218 in cervical carcinoma cells. Oncogene. 2008; 27:2575-2582.
5. Gu W, An J, Ye P, Zhao KN and Antonsson A. Prediction of conserved microRNAs from skin and mucosal human papillomaviruses. Arch Virol. 2011; 156:1161-1171.
6. Li JH, Xiao X, Zhang YN, Wang YM, Feng LM, Wu YM and Zhang YX. MicroRNA miR-886-5p inhibits apoptosis by down-regulating Bax expression in human cervical carcinoma cells. Gynecologic oncology. 2011; 120:145-151.
7. Landgraf P, Rusu M, Sheridan R, Sewer A, Iovino N, Aravin A, Pfeffer S, Rice A, Kamphorst AO, Landthaler M, Lin C, Socci ND, Hermida L, Fulci V, Chiaretti S, Foa R, et al. A mammalian microRNA expression atlas based on small RNA library sequencing. Cell. 2007; 129:1401-1414.
8. Yang JH, Shao P, Zhou H, Chen YQ and Qu LH. deepBase: a database for deeply annotating and mining deep sequencing data. Nucleic Acids Res. 2010; 38:D123-130.
9. Nandy C, Mrazek J, Stoiber H, Grasser FA, Huttenhofer A and Polacek N. Epstein-barr virus-induced expression of a novel human vault RNA. J Mol Biol. 2009; 388:776-784.
10. Stadler PF, Chen JJ, Hackermuller J, Hoffmann S, Horn F, Khaitovich P, Kretzschmar AK, Mosig A, Prohaska SJ, Qi X, Schutt K and Ullmann K. Evolution of vault RNAs. Mol Biol Evol. 2009; 26:1975-1991.
11. Lee K, Kunkeaw N, Jeon SH, Lee I, Johnson BH, Kang GY, Bang JY, Park HS, Leelayuwat C and Lee YS. Precursor miR-886, a novel noncoding RNA repressed in cancer, associates with PKR and modulates its activity. RNA. 2011; 17:1076-1089.
12. Berger W, Steiner E, Grusch M, Elbling L and Micksche M. Vaults and the major vault protein: novel roles in signal pathway regulation and immunity. Cell Mol Life Sci. 2009; 66:43-61.
13. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116:281-297.
14. Dueck A, Ziegler C, Eichner A, Berezikov E and Meister G. microRNAs associated with the different human Argonaute proteins. Nucleic Acids Res. 2012; 40:9850-9862.
15. Flores-Jasso CF, Salomon WE and Zamore PD. Rapid and specific purification of Argonaute-small RNA complexes from crude cell lysates. RNA. 2013; 19:271-279.
16. Kawamura Y, Saito K, Kin T, Ono Y, Asai K, Sunohara T, Okada TN, Siomi MC and Siomi H. Drosophila endogenous small RNAs bind to Argonaute 2 in somatic cells. Nature. 2008; 453:793-797.
17. Marroni M, Agrawal ML, Kight K, Hallene KL, Hossain M, Cucullo L, Signorelli K, Namura S, Bingaman W and Janigro D. Relationship between expression of multiple drug resistance proteins and p53 tumor suppressor gene proteins in human brain astrocytes. Neuroscience. 2003; 121:605-617.
18. An HJ, Ryu SJ, Kim SY, Choi HR, Chung JH and Park SC. Age associated high level of major vault protein is p53 dependent. Cell biochemistry and function. 2009; 27:289-295.
19. Betel D, Koppal A, Agius P, Sander C and Leslie C. Comprehensive modeling of microRNA targets predicts functional non-conserved and non-canonical sites. Genome biology. 2010; 11:R90.
20. Chen XL, Wang H, Zhang XM, Liu HQ and Liu SL. [Establishment of a cisplatin-resistant human cervical cancer cell line]. Sichuan Da Xue Xue Bao Yi Xue Ban. 2012; 43:151-155.
21. Huang H, Huang SY, Chen TT, Chen JC, Chiou CL and Huang TM. Cisplatin restores p53 function and enhances the radiosensitivity in HPV16 E6 containing SiHa cells. Journal of cellular biochemistry. 2004; 91:756-765.
22. Lee KS, Park JL, Lee K, Richardson LE, Johnson BH, Lee HS, Lee JS, Kim SB, Kwon OH, Song KS, Kim YS, Ashktorab H, Smoot DT, Jeon SH, Kim SY and Lee YS. nc886, a non-coding RNA of anti-proliferative role, is suppressed by CpG DNA methylation in human gastric cancer. Oncotarget. 2014; 5:3944-3955.
23. Pillai MM, Yang X, Balakrishnan I, Bemis L and Torok-Storb B. MiR-886-3p down regulates CXCL12 (SDF1) expression in human marrow stromal cells. PloS one. 2010; 5:e14304.
24. Izquierdo MA, Scheffer GL, Schroeijers AB, de Jong MC and Scheper RJ. Vault-related resistance to anticancer drugs determined by the expression of the major vault protein LRP. Cytotechnology. 1998; 27:137-148.
25. Persson H, Kvist A, Vallon-Christersson J, Medstrand P, Borg A and Rovira C. The non-coding RNA of the multidrug resistance-linked vault particle encodes multiple regulatory small RNAs. Nat Cell Biol. 2009; 11:1268-1271.
26. Mashima T, Kudo M, Takada Y, Matsugami A, Gopinath SC, Kumar PK and Katahira M. Interactions between antitumor drugs and vault RNA. Nucleic Acids Symp Ser (Oxf). 2008; :217-218.
27. Lee HS, Lee K, Jang HJ, Lee GK, Park JL, Kim SY, Kim SB, Johnson BH, Zo JI, Lee JS and Lee YS. Epigenetic silencing of the non-coding RNA nc886 provokes oncogenes during human esophageal tumorigenesis. Oncotarget. 2014; 5:3472-3481.
28. Kunkeaw N, Jeon SH, Lee K, Johnson BH, Tanasanvimon S, Javle M, Pairojkul C, Chamgramol Y, Wongfieng W, Gong B, Leelayuwat C and Lee YS. Cell death/proliferation roles for nc886, a non-coding RNA, in the protein kinase R pathway in cholangiocarcinoma. Oncogene. 2013; 32:3722-3731.
29. Cao J, Song Y, Bi N, Shen J, Liu W, Fan J, Sun G, Tong T, He J, Shi Y, Zhang X, Lu N, He Y, Zhang H, Ma K, Luo X, et al. DNA methylation-mediated repression of miR-886-3p predicts poor outcome of human small cell lung cancer. Cancer research. 2013; 73:3326-3335.
30. Treppendahl MB, Qiu X, Sogaard A, Yang X, Nandrup-Bus C, Hother C, Andersen MK, Kjeldsen L, Mollgard L, Hellstrom-Lindberg E, Jendholm J, Porse BT, Jones PA, Liang G and Gronbaek K. Allelic methylation levels of the noncoding VTRNA2-1 located on chromosome 5q31.1 predict outcome in AML. Blood. 2012; 119:206-216.
31. Le Beau MM, Albain KS, Larson RA, Vardiman JW, Davis EM, Blough RR, Golomb HM and Rowley JD. Clinical and cytogenetic correlations in 63 patients with therapy-related myelodysplastic syndromes and acute nonlymphocytic leukemia: further evidence for characteristic abnormalities of chromosomes no. 5 and 7. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 1986; 4:325-345.
32. Fairman J, Chumakov I, Chinault AC, Nowell PC and Nagarajan L. Physical mapping of the minimal region of loss in 5q-chromosome. Proceedings of the National Academy of Sciences of the United States of America. 1995; 92:7406-7410.
33. Balachandran S, Kim CN, Yeh WC, Mak TW, Bhalla K and Barber GN. Activation of the dsRNA-dependent protein kinase, PKR, induces apoptosis through FADD-mediated death signaling. The EMBO journal. 1998; 17:6888-6902.
34. Friedrich I, Eizenbach M, Sajman J, Ben-Bassat H and Levitzki A. A cellular screening assay to test the ability of PKR to induce cell death in mammalian cells. Molecular therapy: the journal of the American Society of Gene Therapy. 2005; 12:969-975.
35. Walerych D, Napoli M, Collavin L and Del Sal G. The rebel angel: mutant p53 as the driving oncogene in breast cancer. Carcinogenesis. 2012; 33:2007-2017.
36. Starks AM, Martin DN, Dorsey TH, Boersma BJ, Wallace TA and Ambs S. Household income is associated with the p53 mutation frequency in human breast tumors. PloS one. 2013; 8:e57361.
37. Scheffner M. Ubiquitin, E6-AP, and their role in p53 inactivation. Pharmacol Ther. 1998; 78:129-139.
38. Kessis TD, Slebos RJ, Nelson WG, Kastan MB, Plunkett BS, Han SM, Lorincz AT, Hedrick L and Cho KR. Human papillomavirus 16 E6 expression disrupts the p53-mediated cellular response to DNA damage. Proceedings of the National Academy of Sciences of the United States of America. 1993; 90:3988-3992.
39. Khoury MP and Bourdon JC. The isoforms of the p53 protein. Cold Spring Harb Perspect Biol. 2010; 2:a000927.
40. Olivares-Illana V and Fahraeus R. p53 isoforms gain functions. Oncogene. 2010; 29:5113-5119.
41. Hofstetter G, Berger A, Berger R, Zoric A, Braicu EI, Reimer D, Fiegl H, Marth C, Zeimet AG, Ulmer H, Moll U, Zeillinger R and Concin N. The N-terminally truncated p53 isoform Delta40p53 influences prognosis in mucinous ovarian cancer. Int J Gynecol Cancer. 2012; 22:372-379.
42. Ding B, Chi SG, Kim SH, Kang S, Cho JH, Kim DS and Cho NH. Role of p53 in antioxidant defense of HPVpositive cervical carcinoma cells following H2O2 exposure. J Cell Sci. 2007; 120:2284-2294.
43. Chen J and Kastan MB. 5'-3'-UTR interactions regulate p53 mRNA translation and provide a target for modulating p53 induction after DNA damage. Genes Dev. 2010; 24:2146-2156.
44. Macleod KF, Sherry N, Hannon G, Beach D, Tokino T, Kinzler K, Vogelstein B and Jacks T. p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage. Genes Dev. 1995; 9:935-944.
45. Huang TG, Ip SM, Yeung WS and Ngan HY. Changes in p21WAF1, pRb, Mdm-2, Bax and Bcl-2 expression in cervical cancer cell lines transfected with a p53 expressing adenovirus. Eur J Cancer. 2000; 36:249-256.
46. Honda R and Yasuda H. Association of p19(ARF) with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53. The EMBO journal. 1999; 18:22-27.
47. Naito S, von Eschenbach AC, Giavazzi R and Fidler IJ. Growth and metastasis of tumor cells isolated from a human renal cell carcinoma implanted into different organs of nude mice. Cancer research. 1986; 46:4109-4115.
48. Kong L, Schafer G, Bu H, Zhang Y, Zhang Y and Klocker H. Lamin A/C protein is overexpressed in tissue-invading prostate cancer and promotes prostate cancer cell growth, migration and invasion through the PI3K/AKT/PTEN pathway. Carcinogenesis. 2012; 33:751-759.
49. Kong L, Yu XP, Bai XH, Zhang WF, Zhang Y, Zhao WM, Jia JH, Tang W, Zhou YB and Liu CJ. RbAp48 is a critical mediator controlling the transforming activity of human papillomavirus type 16 in cervical cancer. J Biol Chem. 2007; 282:26381-26391.